A pair of Cooley litigators left for Norton Rose Fulbright to beef up its patent litigation bench for pharma clients ahead of an expected rise in IP-related disputes.
Sanya Sukduang and Jonathan Davies plan to supplement Norton Rose Fulbright’s intellectual property practice with their experience in patent litigation for drugmakers—the “missing component” in the firm’s otherwise “full-service IP group,” Sukduang said in an interview.
The two practiced together for more than a decade at IP firm Finnegan until they joined Cooley in 2020, according to their LinkedIn profiles. Cooley, in an email statement, wished them well.
Norton Rose Fulbright allows ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.